LifeStance Health Group, Inc.
Close on Oct 19, 2026
- Market cap
- $4.56B
- P/E (TTM)
- 90.5
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $435.40M | $0.06 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $403.50M | $0.04 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | After market close | $382.20M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $363.80M | $0.00 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $345.30M | $-0.01 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $333.00M | $0.00 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | $325.50M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $312.70M | $-0.02 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 2, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | third quarter of 2026 | $49.00M to $59.00M | New |
| Adjusted EBITDAnon-GAAP | full year | $215.00M to $235.00M | Raised |
| Center Marginnon-GAAP | third quarter of 2026 | $140.00M to $152.00M | New |
| Center Marginnon-GAAP | full year | $570.00M to $594.00M | Raised |
| full year revenue | full year | $1.69B to $1.73B | Raised |
| total revenue | third quarter of 2026 | $420.00M to $440.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements LifeStance Health filed with the SEC
VP of Finance & Investor Relations
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reimagining Mental Health Q2 2026 Earnings Presentation August 6, 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q1 2026 Earnings Presentation May 7, 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reimagining Mental Health Q4 2025 Earnings Presentation February 25, 2026 Exhibit 99.2
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q3 2025 Earnings Presentation November 6, 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q2 2025 Earnings Presentation August 7, 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LIFESTANCE NAMES VAUGHN PAUNOVICH AS CHIEF TECHNOLOGY OFFICER
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q1 2025 Earnings Presentation May 7, 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LifeStance Appoints Dave Bourdon as CEO; Ken Burdick Named Executive Chairman
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q4 2024 Earnings Presentation February 27, 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q3 2024 Earnings Presentation November 7, 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q2 2024 Earnings Presentation August 8, 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q1 2024 Earnings Presentation May 9, 2024 Exhibit 99.2
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
VP of Finance & Investor Relations
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q4 2023 Earnings Presentation February 28, 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LifeStance Reports Third Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q3 2023 Earnings Presentation November 8, 2023 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LifeStance Reports Second Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reimagining Mental Health Q2 2023 Earnings Presentation August 9, 2023 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LifeStance Reports First Quarter 2023 Results
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Reimagining Mental Health Q1 2023 Earnings Presentation May 10, 2023 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99#2 to Form 8-K
LifeStance Reports Fourth Quarter and Full Year 2022 Results
Results of operations · Charter or bylaw amendment · Regulation FD disclosure · EX-99 to Form 8-K
Reimagining Mental Health Q4 2022 Earnings Presentation March 8, 2023 Exhibit 99.2
Results of operations · Charter or bylaw amendment · Regulation FD disclosure · EX-99#2 to Form 8-K
LifeStance Reports Third Quarter 2022 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q3 2022 Earnings Presentation November 8, 2022 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LIFESTANCE HEALTH APPOINTS J. MICHAEL BRUFF AS NEW BUSINESS TRANFORMATION OFFICER; DAVID BOURDON AS CHIEF
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
LifeStance Health Appoints Ken Burdick as CEO and Chairman; Founding CEO and Chairman Michael Lester Retires
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
LifeStance Reports Second Quarter 2022 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2022 Earnings Presentation August 9, 2022 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
LIFESTANCE HEALTH NAMES DANISH QURESHI AS CHIEF OPERATING OFFICER, EFFECTIVE JULY 1, 2022
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
LifeStance Reports First Quarter 2022 Results
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K